Market Overview

Lion Biotechnologies Announces Publication of Data from Study of Metastatic Cervical Cancer Patients Treated with HPV


Lion Biotechnologies, Inc.
(Nasdaq: LBIO), a biotechnology company that is developing novel cancer
immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced
that data from a metastatic cervical cancer study conducted by the National
Cancer Institute (NCI) was published in the Journal of Clinical Oncology in an
article titled "Complete Regression of Metastatic Cervical Cancer After
Treatment With Human Papillomavirus-Targeted Tumor-Infiltrating T Cells". Data
from the trial showed objective responses, including durable, complete
regressions, in patients after a single infusion of HPV-TIL.

The trial was designed to determine if the infusion of human papillomavirus
tumor-infiltrating lymphocytes (HPV-TIL) could induce regression of advanced
HPV-positive cancers.

Of the nine metastatic cervical cancer patients who were enrolled and treated
with HPV-TIL, three patients experienced objective tumor responses, two of
whom experienced complete, ongoing remissions of 22 and 15 months,
respectively. The other patient demonstrated a partial response of three

"We are pleased to see the results of this trial, which demonstrate potential
efficacy of TIL treatment in metastatic cervical cancer, a notoriously
difficult-to-treat cancer in women," said Elma Hawkins, PhD, Lion's president
and chief executive officer. "We recently amended our CRADA with the NCI to
include technologies based on the HPV-TIL research. With these technologies,
we look forward to expanding our clinical programs and developing new
treatment options for patients with cervical cancer and other solid tumors."


Related Articles (LBIO)

View Comments and Join the Discussion!

Posted-In: News Press Releases

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at